Business
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Study Combinations of Novel Viral Immunotherapy
About this update from Candel Therapeutics, Inc.
[{"type":"text","content":"Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy Candidates in Solid Tumor ModelsUpcoming clinical data presentations at SITC and SNO Annual MeetingsVirtual R&D Day on December 6, 2022, with Candel leadership and renowned oncology experts NEEDHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. “Candel made important progress across multiple facets of the organization this quarter,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “We have bolstered the Company’s capabilities and future potential with the appointment of three new board members and two new leadership executives, an orphan drug designation from the European Commission for CAN-2409 in glioma, and most recently a discovery partnership with the University of Pennsylvania’s Center for Cellular Immunotherapies, led by Dr. Carl June, the Richard W. Vague Professor for Immunotherapy, to study the combination of our enLIGHTEN™ Discovery Platform and their CAR-T cells in solid tumors. We will close the year with new clinical results coming from our pipeline being presented at R&D Day and we look ahead with confidence to deliver our world-class viral immunotherapy candidates to patients battling cancer.” Jason A. Amello, Chief Financial Officer, added, “The third quarter of 2022 was marked by significant momentum as the Company broadened its viral immunotherapy footprint and continued to execute across all of its programs in an efficient and cost-effective manner.” Third Quarter 2022 and Recent Highlights In August, the Company enhanced its Board of Directors with the appointments of three new Board members. (View Release) Joseph Papa, Chief Executive Officer of Bausch + Lomb CorporationGary Nabel, MD, PhD, Chief Innovation Officer of OPKO and Chief Executive Officer, ModeX Therapeutics, Inc., an OPKO Health companyRenee Gaeta, Chief Financial Officer of Eko Devices In September, the Company strengthened its executive leadersh...